Thermo apparently made a $30bn offer for Illumina, though neither party has commented on the speculations, and analysts argue it would make no sense for either party: https://www.genomeweb.com/sequencing/analysts-pour-cold-water-rumor-thermo-fisher-making-acquisition-bid-illumina.

The ExAC paper is out, http://www.nature.com/nature/journal/v536/n7616/full/nature19057.html, and something more accessible from STAT: https://www.statnews.com/2016/08/17/genetic-variants-ex-ac-sequence. I already covered some of the results of this >60,000 exomes analysis when the article appeared in preprint, but its important enough to recap:

• Each ExAC subject has ~54 variants classified as causing a genetic disorder, almost all of which are false positives. i.e. ExAC highlights how bad existing databases are — because of their reliance of studies of very small sample size
• 99% have a frequency of <1%; 54% are singletons (variants seen only once in the data set); 72% are absent from both 1000G and ESP data sets
• It covers: one variant for every 8 base pairs (bp) within the exome intervals; 7.5% of all possible synonymous variants; 63.1% of possible CpG transitions (C to T variants, in which the adjacent base is G); 3% of possible transversions; 9.2% of other possible transitions
• 72% of LoF-intolerant genes have not yet been assigned a human disease phenotype despite clear evidence for extreme selective constraint
• Filtering on the highest allele frequency in any one population (‘popmax’) rather than the average (‘global’) allele frequency was best for identifying pathogenic variants
• “The abundance of rare functional variation in many disease genes in ExAC is a reminder that such variants should not be assumed to be causal or highly penetrant without careful segregation or case-control analysis”
• Average individual has 85 heterozygous and 35 homozygous protein truncating variants (PTVs), only ~2 singletons
• “discovery of homozygous PTVs is markedly enhanced in the South Asian samples, which come primarily from a Pakistani cohort with 38.3% of individuals self-reporting as having closely related parents, emphasizing the extreme value of consanguineous cohorts for human knockout discovery”

Related stories

• Many variants previously reported pathogenic are now considered benign, particularly as the result of large scale analyses that show some of these variants are fairly frequent in the population. This misclassification has particularly affected those of African descent, a study on cardiac variants reports. This is largely because of the lack of individuals of African descent in large scale population databases. http://www.nejm.org/doi/full/10.1056/NEJMsa1507092
• A study of mutational rates across cardiac genes makes the case for domain by domain knowledge in variant interpretation, and points to much misclassification in databases: http://www.nature.com/gim/journal/vaop/ncurrent/full/gim201690a.html
• In a paper entitled “Using Genetic Technologies To Reduce, Rather Than Widen, Health Disparities”, a group of academics make the case for policy to ensure non-hispanic whites do not get the majority of the benefits from genomics:  http://content.healthaffairs.org/content/35/8/1367

 

Quest/Athena have replied to Amy William’s in the latest step in this genetic-testing drama. Recap: Athena, now owned by Quest, reported a mutation in the plaintiff’s son, Christian, as a Variant of Uncertain Significance. The variant is now reported as pathogenic for Dravet syndrome, a diagnosis which, if made at the time, would have altered Christian’s course of treatment and possibly saved his life (he died age 2). The report, issued in 2007, was sent to Christian’s clinical geneticist, with the recommendation that the parents be tested to assess whether or not the variant was de novo. Ms Williams says she never saw the report. Quest/Athena have asked for the case to be dismissed, and that decision is pending. “If allowed to go forward, legal experts believe that Williams v Quest/Athena could define what constitutes the standard of care for a genetic testing lab.” https://www.genomeweb.com/molecular-diagnostics/quest-athena-reply-plaintiffs-wrongful-death-lawsuit

Oxford Nanopore and Illumina have reached a settlement over the latter’s suing of the former. The case settled on a particular protein pore, which is not used in the latest ONT product anyway: http://www.sciencemag.org/news/2016/03/gene-sequencing-technology-sparks-patent-fight-shrouded-mystery

Foundation Medicine has submitted its FoundationOne product to parallel review by the FDA and CMS: https://www.genomeweb.com/sequencing/foundation-medicine-pursuing-parallel-review-fda-cms-foundationone. “If approved, FoundationOne could be the first FDA-approved comprehensive genomic profiling assay to incorporate multiple companion diagnostics to support precision medicine in oncology, including an indication for use as a companion diagnostic across a diverse range of solid tumors.”

A documentary about the Undiagnosed (http://www.undiagnosedfilm.com/) has spawned a consortium dedicated to extending genomic analysis of six undiagnosed individuals to contextual info beyond the genome. The participants (in academe and industry) met on the 16th August to assess their results, though the rest of us may have to wait until the film airs in early 2017 to hear how they did. This endeavor is a follow on from the CLARITY challenge.

George Church’s lab is nearing completion of an E-coli genome engineered to use a different genetic code – one that eliminates 7 ‘redundant’ codons, thus freeing them up for potential reuse: http://www.sciencemag.org/news/2016/08/biologists-are-close-reinventing-genetic-code-life

A systematic review of the potential integration of WES into clinical care found interpretation of variants of unknown significance, incidental findings, and the cost and reimbursement of WES-based tests as the most commonly reported challenges. https://bmcmedgenomics.biomedcentral.com/articles/10.1186/s12920-016-0213-6

A blog article making the case for the relevance of genomics to public health (from the Director of the Office of Public Health Genomics, Centers for Disease Control and Prevention): http://blogs.cdc.gov/genomics/2016/07/13/five-misconceptions/

Blood forming stem cells have been extracted from patients with sickle cell disease, and modified using CRISPR to produce high (and healthy) levels of foetal haemoglobin: http://www.frontlinegenomics.com/news/7137/crispr-gene-editing-reveals-new-therapeutic-approach-for-blood-disorders/

Some cancer-treatment combos work better if the tumor has a higher mutational load: http://science.sciencemag.org/content/348/6230/124.long

The Human Functional Genomes Project, which aims to large-scale map genetic variation to functional consequence, has published data on 500 individuals related to immune response, and has more similar projects in the pipeline: https://www.genomeweb.com/sequencing/human-functional-genomics-project-begins-unraveling-links-between-genes-immune-response

Weaver, a new graph based variant caller from U of Illinois, focused on somatic samples and structural variation. https://www.genomeweb.com/informatics/new-algorithm-simultaneously-identifies-structural-variants-copy-number-changes-cancer

The UK’s project to do WES or WGS pre-natally, after abnormal ultrasound, is starting to return results to clinical teams: https://www.genomeweb.com/molecular-diagnostics/uks-prenatal-genome-and-exome-study-aims-improve-diagnosis-after-abnormal

Counsyl have made the scientific case for expanded carrier screening over existing guidelines (which are more targeted). Their business model rests on such screening. http://jama.jamanetwork.com/article.aspx?articleid=2544641

Google are continuing their push into genomics, with a big partnership with Stanford Health announced: https://www.genomeweb.com/informatics/google-stanford-rework-research-algorithms-planned-clinical-genomics-service

Oxford Nanopore have announced they can now do direct sequencing of RNA: https://www.genomeweb.com/sequencing/oxford-nanopore-develops-direct-rna-sequencing-protocol

How did life on earth begin? Before the modern relationship between DNA and RNA, the “RNA world” hypothesis is that RNA acted both as storer of information and as cellular catalyst. That story just garnered extra weight by the creation of an RNA molecule that can make copies from other RNA molecules (it can’t copy itself, thats a hope of future research). The study used in vitro evolution. http://www.sciencemag.org/news/2016/08/newly-made-rna-strand-bolsters-ideas-about-how-life-earth-began

New study of bacterial evolution shows that most new persisted mutations are beneficial: http://www.frontlinegenomics.com/press-release/6951/bacteria-show-capacity-rapid-beneficial-mutations